Cargando…
Strategies for Delivery of siRNAs to Ovarian Cancer Cells
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, t...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835428/ https://www.ncbi.nlm.nih.gov/pubmed/31652539 http://dx.doi.org/10.3390/pharmaceutics11100547 |
_version_ | 1783466669959544832 |
---|---|
author | Farra, Rossella Maruna, Matea Perrone, Francesca Grassi, Mario Benedetti, Fabio Maddaloni, Marianna El Boustani, Maguie Parisi, Salvo Rizzolio, Flavio Forte, Giancarlo Zanconati, Fabrizio Cemazar, Maja Kamensek, Urska Dapas, Barbara Grassi, Gabriele |
author_facet | Farra, Rossella Maruna, Matea Perrone, Francesca Grassi, Mario Benedetti, Fabio Maddaloni, Marianna El Boustani, Maguie Parisi, Salvo Rizzolio, Flavio Forte, Giancarlo Zanconati, Fabrizio Cemazar, Maja Kamensek, Urska Dapas, Barbara Grassi, Gabriele |
author_sort | Farra, Rossella |
collection | PubMed |
description | The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. |
format | Online Article Text |
id | pubmed-6835428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68354282019-11-25 Strategies for Delivery of siRNAs to Ovarian Cancer Cells Farra, Rossella Maruna, Matea Perrone, Francesca Grassi, Mario Benedetti, Fabio Maddaloni, Marianna El Boustani, Maguie Parisi, Salvo Rizzolio, Flavio Forte, Giancarlo Zanconati, Fabrizio Cemazar, Maja Kamensek, Urska Dapas, Barbara Grassi, Gabriele Pharmaceutics Review The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. MDPI 2019-10-22 /pmc/articles/PMC6835428/ /pubmed/31652539 http://dx.doi.org/10.3390/pharmaceutics11100547 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Farra, Rossella Maruna, Matea Perrone, Francesca Grassi, Mario Benedetti, Fabio Maddaloni, Marianna El Boustani, Maguie Parisi, Salvo Rizzolio, Flavio Forte, Giancarlo Zanconati, Fabrizio Cemazar, Maja Kamensek, Urska Dapas, Barbara Grassi, Gabriele Strategies for Delivery of siRNAs to Ovarian Cancer Cells |
title | Strategies for Delivery of siRNAs to Ovarian Cancer Cells |
title_full | Strategies for Delivery of siRNAs to Ovarian Cancer Cells |
title_fullStr | Strategies for Delivery of siRNAs to Ovarian Cancer Cells |
title_full_unstemmed | Strategies for Delivery of siRNAs to Ovarian Cancer Cells |
title_short | Strategies for Delivery of siRNAs to Ovarian Cancer Cells |
title_sort | strategies for delivery of sirnas to ovarian cancer cells |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835428/ https://www.ncbi.nlm.nih.gov/pubmed/31652539 http://dx.doi.org/10.3390/pharmaceutics11100547 |
work_keys_str_mv | AT farrarossella strategiesfordeliveryofsirnastoovariancancercells AT marunamatea strategiesfordeliveryofsirnastoovariancancercells AT perronefrancesca strategiesfordeliveryofsirnastoovariancancercells AT grassimario strategiesfordeliveryofsirnastoovariancancercells AT benedettifabio strategiesfordeliveryofsirnastoovariancancercells AT maddalonimarianna strategiesfordeliveryofsirnastoovariancancercells AT elboustanimaguie strategiesfordeliveryofsirnastoovariancancercells AT parisisalvo strategiesfordeliveryofsirnastoovariancancercells AT rizzolioflavio strategiesfordeliveryofsirnastoovariancancercells AT fortegiancarlo strategiesfordeliveryofsirnastoovariancancercells AT zanconatifabrizio strategiesfordeliveryofsirnastoovariancancercells AT cemazarmaja strategiesfordeliveryofsirnastoovariancancercells AT kamensekurska strategiesfordeliveryofsirnastoovariancancercells AT dapasbarbara strategiesfordeliveryofsirnastoovariancancercells AT grassigabriele strategiesfordeliveryofsirnastoovariancancercells |